DICE Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on DICE Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how DICE Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with DICE Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Dice Therapeutics Inc (DICE Therapeutics), a subsidiary of Eli Lilly and Co is a biopharmaceutical company that focuses on the discovery and development of innovative oral drug candidates to treat chronic diseases in immune disorders and other therapeutic areas. It focuses on the development of oral therapies to treat well-validated conditions in immune disorders to achieve effectiveness comparable to their systemic biologic counterparts, which have shown therapeutic benefits in immune disorders and other areas.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
DICE Therapeutics applies its R&D to enhance its proprietary DELSCAPE platform and identify exclusive oral small molecules with the potential to meet the needs of patients with chronic diseases. The company is developing its lead therapeutic candidate, DC-806 (formerly S011806), for several immune disorder indications.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer